Misplaced Pages

Latest revision as of 20:45, 25 November 2024

This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources in this section. Unsourced material may be challenged and removed. (June 2012) (Learn how and when to remove this message)

Triamterene

Clinical data
Trade names	Dyrenium, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682337
Pregnancy category	AU: C
Routes of administration	By mouth
ATC code	C03DB02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: WARNINGRx-only
Pharmacokinetic data
Bioavailability	30-70%
Protein binding	67%
Metabolism	hydroxylation to para-hydroxytriamterene
Elimination half-life	1-2 hours, active metabolite 3 hours
Excretion	renal <50%, 21% unchanged
Identifiers
IUPAC name 6-phenylpteridine-2,4,7-triamine
CAS Number	396-01-0
PubChem CID	5546
IUPHAR/BPS	4329
DrugBank	DB00384
ChemSpider	5345
UNII	WS821Z52LQ
KEGG	D00386
ChEMBL	ChEMBL585
CompTox Dashboard (EPA)	DTXSID6021373
ECHA InfoCard	100.006.278
Chemical and physical data
Formula	C12H11N7
Molar mass	253.269 g·mol
InChI InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19) Key:FNYLWPVRPXGIIP-UHFFFAOYSA-N
(what is this?)  (verify)

Triamterene (traded under names such as Dyrenium and Dytac) is a potassium-sparing diuretic often used in combination with thiazide diuretics for the treatment of high blood pressure or swelling. The combination with hydrochlorothiazide, is known as hydrochlorothiazide/triamterene.

Side effects

Common side effects may include a depletion of sodium, folic acid, and calcium, nausea, vomiting, diarrhea, headache, dizziness, fatigue, and dry mouth. Serious side effects may include heart palpitations, tingling/numbness, fever, chills, sore throat, rash, and back pain. Triamterene can also cause kidney stones through direct crystallization or by seeding calcium oxalate stones. Triamterene is best avoided in patients with chronic kidney disease due to the possibility of hyperkalemia. People using this drug should use salt substitute cautiously.

Triamterene may impart a blue fluorescent color to the urine.

Caution with certain disease states

Diabetes: Use with caution in people with prediabetes or diabetes mellitus as there may be a change in glucose control.

Liver impairment: Use with caution in people with severe liver dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.

Kidney failure: combined triamterene and indomethacin therapy caused reversible acute kidney injury in some people.

Kidney stones: Use with caution in people with kidney stones.

Use should be avoided if the creatinine clearance is less than 10 ml/minute.

Mechanism of action

Triamterene directly blocks the epithelial sodium channel (ENaC) on the lumen side of the kidney collecting tubule. Other diuretics cause a decrease in the sodium concentration of the forming urine due to the entry of sodium into the cell via the ENaC, and the concomitant exit of potassium from the principal cell into the forming urine. Blocking ENaC prevents this from happening. Amiloride works in the same way. Sodium channel blockers directly inhibit the entry of sodium into the sodium channels.

With hydrochlorothiazide

Triamterene is commonly prepared in combination with hydrochlorothiazide for treatment of hypertension (high blood pressure) and edema (water retention). This combination is in a class of medications called diuretics or 'water pills', and causes the kidneys to get rid of the body's unneeded water and sodium through the urine.

History

The triamterene ring system is found in many naturally occurring compounds, such as folic acid and riboflavin. The observation that the naturally occurring compound xanthopterin had renal affects led scientists at Smith Kline and French Laboratories in Philadelphia to begin a medicinal chemistry campaign to discover potential drugs, as part of a program to discover potassium-sparing diuretics. The first clinical studies were published in 1961 and the first trials combining it with hydrochlorothiazide were published the next year.

Smith Kline & French launched it as a single agent under the brand Dyrenium in 1964. The combination drug with hydrochlorothiazide, Dyazide, was first approved in the US in 1965 and the first generic, brought by Bolar Pharmaceutical Co., was approved in 1987. In 1986 Dyazide was the most prescribed drug in the US and had $325 million in sales, making it SmithKline Beckman's second-biggest seller behind Tagamet.

The patents had expired on Dyazide in 1980, but complications arose with the introductions of generics, because the formulation of Dyazide resulted in variable batches that made it impossible for generic manufacturers to show that their versions were bioequivalent.

Bolar Pharmaceutical was in the running to be the first to bring a generic, but its application was delayed by these concerns about whether its formulation provided the same amount of each drug; these were complicated by accusations that Bolar had fraudulently substituted Dyazide for its own version to conduct studies that were submitted to the FDA. Shortly after Bolar's generic was approved, further concerns were raised with regard to Bolar's applications to market generics more generally; these findings among others raised widespread concern among doctors and the public over whether generics were really the same as branded drugs. Bolar ended up recalling its generic form of Dyazide and withdrawing the product in 1990. In 1991 the US Justice Department on behalf of the FDA filed 20 criminal charges against Bolar for its fraud, and early the next year Bolar pled guilty and agreed to pay a $10M fine. Public concern over the safety of generic drugs was further exacerbated by a Congressional investigation into bribery at the FDA by generics companies that found pervasive corruption; the investigation had been spurred by the generics company Mylan, which had hired private investigators based on its beliefs that competitors were getting unfair advantages in getting their generics approved.

Mylan itself developed a version of a triamterene/hydrochlorothiazide combination drug after the Dyazide patent expired, and used a different, more stable formulation as well as different dosages of each active ingredient (50 mg hydrochlorothiazide and 75 mg triamterene, compared with Dyazide's 25 mg hydrochlorothiazide and 50 mg triamterene) so it had to get approval as a new drug, as opposed to a generic; their product was called Maxzide and was approved in 1984. The higher dose allowed once per day dosing, which Mylan and its marketing partner, Lederle, believed would help it compete against Dyazide, which had $210M in sales in 1983.

Mylan's patents on the drug were declared invalid in court, and its marketing exclusivity expired in 1987, prompting a rush of generic competition and litigation by two of them, American Therapeutics Inc. and Vitarine Pharmaceuticals, with the FDA. Vitarine, along with Par Pharmaceutical, were two of the companies that Mylan had targeted in its investigation into corruption and it turned out that Par and Vitarine had each used Mylan's Maxzide to obtain its bioequivalence data, leading both companies to withdraw its generic competitor to Mylan's product. Generics eventually entered the market.

Research

While there is a lack of randomized controlled trials evaluating the use of triamterene in the treatment of Ménière's disease, the typical treatment is 37.5 mg of triamterene with 25 mg of hydrochlorothiazide 1–2 capsules daily. This recommendation was given a Strength of Recommendation Taxonomy (SORT) grade of C.

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. "Advisory Statement" (PDF). LoSalt. Archived from the original (PDF) on 10 December 2005.
3. Favre L, Glasson P, Vallotton MB (March 1982). "Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects". Annals of Internal Medicine. 96 (3): 317–320. doi:10.7326/0003-4819-96-3-317. PMID 6949485.
4. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, et al. (September 1996). "Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis". Pflügers Archiv. 432 (5): 760–766. doi:10.1007/s004240050196. PMID 8772124. S2CID 10489391.
5. ^ Fink CA, McKenna JM, Werner LH (2003). "Diuretic and Uricosuric Agents". In Abraham DJ (ed.). Burger's medicinal chemistry and drug discovery. Volume 3: Cardiovascular Agents and Endocrines (6th ed.). Wiley. pp. 55–154. ISBN 978-0471370291.
6. "Triamterene and Hydrochlorothiazide". MedlinePlus. U.S. National Library of Medicine. National Institutes of Health. 1 September 2008.
7. Crosley AP, Ronquillo LM, Strickland WH, Alexander F (February 1962). "Triamterene, a new natruretic agent. Preliminary observations in man". Annals of Internal Medicine. 56 (2): 241–251. doi:10.7326/0003-4819-56-2-241. PMID 13882367.
8. Heath WC, Freis ED (October 1963). "Triamterene with Hydrochlorothiazide in the Treatment of Hypertension". JAMA. 186 (2): 119–122. doi:10.1001/jama.1963.03710020039012. PMID 14056525.
9. Landau R, Achilladelis B, Scriabine A (1999). Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation series in innovation and entrepreneurship. Vol. 2. Chemical Heritage Foundation. ISBN 9780941901215.
10. FDA "Approval History NDA 016042: Dyazide". U.S. Food and Drug Administration. Retrieved 8 September 2016.
11. ^ Wolf R (22 August 1987). Smithkline Loses Exclusive Rights To Drug. The Philadelphia Inquirer. Archived from the original on September 26, 2015.
12. Boehm G, Yao L, Han L, Zheng Q (September 2013). "Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984". Acta Pharmaceutica Sinica B. 3 (5): 297–311. doi:10.1016/j.apsb.2013.07.004.
13. ^ Seaman J, Landry JT (2011). Mylan 50 Years of Unconventional Success. University Press of New England. p. 50. ISBN 9781611682700.
14. Strickland C (15 October 1989). "Bolar: A Drug Company Under Siege". The New York Times.
15. Cimons M (29 August 1989). "FDA to Lift OK of Last Dyazide Generic Version". Los Angeles Times.
16. "Bolar Recalls Generic Version Of Dyazide And Extended Release Phenytoin, Saying "Bioequivalence Cannot Be Assured"; Products; Represent 52% of Sales". Pink Sheet. February 5, 1990.
17. Shaw D (February 27, 1991). "U.S. Charges Bolar Pharmaceutical With Misrepresenting Its Products". The Philadelphia Inquirer. Archived from the original on September 16, 2016.
18. Freudenheim M (28 February 1991). "Bolar Plans Guilty Plea On Generics". The New York Times.
19. ^ Freudenheim M (10 September 1989). "Exposing the F.D.A." The New York Times.
20. "Approval History NDA 019129: Maxzide". U.S. Food and Drug Administration. Retrieved 8 September 2016.
21. ^ "Mylan's Maxzide is "Approvable" at FDA: Lederle To Market Brand Competition to Smithkline's No. 3-Ranked Dyazide; Final Approval Anticipated "Imminently"". Pink Sheet. 22 October 1984.
22. Reid K (November 17, 1987). "US Judge to Rule on Drug Marketing". Journal of Commerce.
23. Andrews EL (31 July 1989). "F.D.A. Inquiry on Generic Drugs Focuses on Changes in Ingredients". The New York Times.
24. "Generic Maxzide". Drugs.com. Retrieved 8 September 2016.
25. Swartz R, Longwell P (March 2005). "Treatment of vertigo" (PDF). American Family Physician. 71 (6): 1115–1122. PMID 15791890.
26. Sloane PD, Coeytaux RR, Beck RS, Dallara J (May 2001). "Dizziness: state of the science". Annals of Internal Medicine. 134 (9 Pt 2): 823–832. doi:10.7326/0003-4819-134-9_Part_2-200105011-00005. PMID 11346317. S2CID 6762911.

External links

• IARC Group 2B carcinogens
• Potassium-sparing diuretics
• Pteridines
• World Anti-Doping Agency prohibited substances